Activate presents at the 2023 Biotech Showcase
Brian Horsburgh, Activate’s CEO, presented on the company’s technology and pipeline at the Biotech Showcase in San Francisco on January 10th. Dr. Horsburgh described how Activate’s technology allows for the delivery of drugs to immune cell targets where they are slowly released. This sustained delivery is critical for optimal immune activity of ACT-3, which is a Toll-like receptor 7 agonist and is poised to enter clinical trials.